GT Apeiron Therapeutics
Mingxi is the CEO of Apeiron Therapeutics. Dr. Li specializes in identifying and commercializing early-stage life science innovation. He started his career at Jiuding Capital, focusing on healthcare investments in China, and led the investment in Zhejiang Chengyi Pharmaceutical (SH: 603811). Mingxi later joined Simcere Pharmaceutical Group managing its $US 200 million investment in life science companies globally. Mingxi graduated from Tsinghua University and received his Ph.D. degree in Biochemistry from the University of Illinois at Urbana-Champaign.
GT Apeiron Therapeutics
Apeiron Therapeutics intends to develop breakthrough investigational medicines by harnessing the power of artificial intelligence which drastically increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials.